Icosavax Inc

NASDAQ ICVX

Download Data

Icosavax Inc Cash Return on Invested Capital (CROIC) 5 year CAGR for the year ending December 31, 2022

Icosavax Inc Cash Return on Invested Capital (CROIC) 5 year CAGR is NA for the year ending December 31, 2022. The cash return on invested capital ratio measures the profitability of a company's invested capital based on its operating cash flow. It is calculated by dividing operating cash flow by the difference between total assets and current liabilities. This ratio indicates the company's ability to generate cash flow relative to the capital invested, excluding short-term liabilities. A higher ratio suggests more efficient cash flow generation from the invested capital. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Icosavax Inc Cash Return on Invested Capital (CROIC) for the year ending December 31, 2022 was -0.27, a -98.10% change year over year.
  • Icosavax Inc Cash Return on Invested Capital (CROIC) for the year ending December 31, 2021 was -0.14, a 89.93% change year over year.
  • Icosavax Inc Cash Return on Invested Capital (CROIC) for the year ending December 31, 2020 was -1.37, a -563.84% change year over year.
  • Icosavax Inc Cash Return on Invested Capital (CROIC) for the year ending December 31, 2019 was -0.21.
NASDAQ: ICVX

Icosavax Inc

CEO Mr. Adam K. Simpson
IPO Date July 29, 2021
Location United States
Headquarters 1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees 60
Sector Healthcare
Industry Biotechnology
Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Similar companies

ABOS

Acumen Pharmaceuticals Inc

NA

NA

DAWN

Day One Biopharmaceuticals Inc

NA

NA

ELDN

Eledon Pharmaceuticals Inc

NA

NA

IMMX

Immix Biopharma Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

FRLN

Freeline Therapeutics Holdings Plc

NA

NA

AVRO

AVROBIO Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email